{"entity":{"id":"nct07011056","kind":"trial","name":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","aka":[],"tldr":"A phase 3 trial testing Purinostat in diffuse large B-cell lymphoma, now recruiting.","summary":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT07011056, led by Chengdu Zenitar Biomedical Technology, and recruiting on the registry. Official title: A Randomised, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Planned enrolment is 390 participants (estimated). The study started in 2025-07-18 and primary completion is expected in 2029-06-30. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07011056","url":"https://clinicaltrials.gov/study/NCT07011056"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["purinostat"],"companies":["chengdu-zenitar-biomedical-technology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07011056","phase":"3","setting":"A Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","sponsor":"Chengdu Zenitar Biomedical Technology","participation":[{"nct":"NCT07011056","source":"https://clinicaltrials.gov/study/NCT07011056","fetchedAt":"2026-10-07T16:55:21.080Z","studySha256":"e5fa95faeec628eb32a9ddc412e4ac43529985f71d5ca86036dfc25f0130bc5a","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-19","leadSponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":390,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-07-18","startedType":"actual","enrolled":390,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07011056/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"purinostat","kind":"drug","name":"Purinostat","route":"/drugs/purinostat/"}],"company":[{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","route":"/companies/chengdu-zenitar-biomedical-technology/"}]}}